Publications
Detailed Information
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Waguespack, Steven G. | - |
dc.contributor.author | Drilon, Alexander | - |
dc.contributor.author | Lin, Jessica J. | - |
dc.contributor.author | Brose, Marcia S. | - |
dc.contributor.author | McDermott, Ray | - |
dc.contributor.author | Almubarak, Mohammed | - |
dc.contributor.author | Bauman, Jessica | - |
dc.contributor.author | Casanova, Michela | - |
dc.contributor.author | Krishnamurthy, Anuradha | - |
dc.contributor.author | Kummar, Shivaani | - |
dc.contributor.author | Leyvraz, Serge | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Sohal, Davendra | - |
dc.contributor.author | Sherman, Eric | - |
dc.contributor.author | Norenberg, Ricarda | - |
dc.contributor.author | Silvertown, Josh D. | - |
dc.contributor.author | Brega, Nicoletta | - |
dc.contributor.author | Hong, David S. | - |
dc.contributor.author | Cabanillas, Maria E. | - |
dc.date.accessioned | 2022-10-11T01:16:28Z | - |
dc.date.available | 2022-10-11T01:16:28Z | - |
dc.date.created | 2022-07-19 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.citation | European Journal of Endocrinology, Vol.187 No.1, pp.631-643 | - |
dc.identifier.issn | 0804-4643 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185751 | - |
dc.description.abstract | © 2022 The authors.Objective: Larotrectinib is a highly selective tropomyosin receptor kinas e (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed t he efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC). Methods: We pooled data from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, and NCT02637687). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints i ncluded duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Data cut-off: July 2020. Results: Twenty-nine patients (median age: 60; range: 6-80) with TRK fu sion-positive TC were treated. Tumour histology was papillary (PTC) in 20 (69%) patients, follicular (FTC) in 2 (7%), and anaplastic (ATC) in 7 (24%) patients. Among 28 evaluable patients, ORR was 71% (95% CI: 51-87); best responses were complete response in 2 (7%) patients, partial response in 18 (64%), stable disease in 4 (14%), progressive di sease in 3 (11%), and undetermined in 1 (4%) due to clinical progression prior to the first post-baseline assessment . ORR was 86% (95% CI: 64-97) for PTC/FTC and 29% (95% CI 4-71) for ATC. Median time to response was 1.87 months (range 1.64-3.68). The 24-month DoR, PFS, and OS rates were 81, 69, and 76%, respectively. Treatment-related adv erse events were mainly grades 1-2. Conclusion: In TRK fusion-positive TC, larotrectinib demonstrates rapid an d durable disease control and a favourable safety profile in patients with advanced disease requiring syste mic therapy. | - |
dc.language | 영어 | - |
dc.publisher | BioScientifica Ltd. | - |
dc.title | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1530/EJE-21-1259 | - |
dc.citation.journaltitle | European Journal of Endocrinology | - |
dc.identifier.wosid | 000836569100010 | - |
dc.identifier.scopusid | 2-s2.0-85129781056 | - |
dc.citation.endpage | 643 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 631 | - |
dc.citation.volume | 187 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.